PCOS weight loss in India: where semaglutide and Mounjaro stand, what the PCOS studies tested, and the pregnancy rules

A national study found PCOS in 7.2 % to 19.6 % of Indian women aged 18 to 40³². That study enrolled 8,993 women across five zones of India from 2018 to 2022³². It used three sets of diagnostic criteria, so it gives three numbers: 7.2 % by NIH 1990 (US National Institutes of Health), 13.6 % by AE-PCOS (Androgen Excess and PCOS Society) and 19.6 % by Rotterdam 2003³². The criteria combine features such as hyperandrogenism (raised male-type hormones), oligomenorrhoea (infrequent periods) and polycystic ovaries³².

Among the 1,224 women with PCOS, 43.2 % had obesity, 32.9 % had fatty liver disease and 24.9 % had metabolic syndrome, a cluster of signs such as a large waist and raised blood sugar^32,34. Impaired glucose tolerance affected 9.1 % and diabetes 3.3 %³². The lead author reported grants from the Indian Council of Medical Research (ICMR); another author reported honoraria from Novo Nordisk, USV and Sun Pharma outside the work³².

The Indian government defines obesity as a body mass index (BMI) of 25 or more, and overweight as 23.00 to 24.99³⁵. An Indian consensus statement says the limits of normal BMI are lower in Asian Indians than in white Caucasians³⁶.

No. Neither medicine lists PCOS among its approved uses in India or in the US^1,2,4,5,6. In India, the news agency PTI reported that Mounjaro was launched for weight management by BMI and for type 2 diabetes¹. CDSCO, India's drug regulator, records Wegovy as approved for chronic weight management in adults². The brands and makers are set out in our pages on semaglutide in India and Mounjaro in India.

The Indian weight indications name a BMI and a weight-related condition; whether PCOS counts is the doctor's decision^1,9. CDSCO's advisory of 10 March 2026 prohibits promotion that could encourage off-label use, meaning use outside the approved indication³⁷.

The six studies below tested 20 to 100 women for a few months; none was run in India^15,16. In a randomised trial, chance decides who gets which treatment³⁸. In a double-blind trial, neither the women nor the researchers know who gets what; in an open-label trial, both know^33,39.

PCOS studies of GLP-1 medicines, from their PubMed abstracts^14,15,16,18. Results are averages for the groups studied, not a forecast for one person. Facts checked on 30 October 2026.

A meta-analysis pools data from different studies on the same subject⁴⁰. One from 2024 pooled 176 women from four placebo-controlled trials; waist size, triglycerides and testosterone fell⁴¹. A 2024 review for the 2023 international PCOS guideline counted 11 trials of anti-obesity medicines and said published data are very limited⁴². A 2026 meta-analysis of 11 trials found a BMI fall of 1.38 kg/m², with low certainty⁴³.

The large weight trials were not PCOS trials. STEP 1 (semaglutide 2.4 mg) gave −14.9 % at 68 weeks and SURMOUNT-1 (tirzepatide) up to −20.9 % at 72 weeks, in adults with obesity^44,45. Novo Nordisk funded STEP 1 and Eli Lilly supported SURMOUNT-1^44,45. The PCOS studies used semaglutide at 0.25 to 1 mg, below the 2.4 mg weight dose, and tirzepatide at 5 mg, the low end of a scale with pens up to 15 mg^{4,15,16,17,46}.

The weight schedules come from the US labels: semaglutide steps up from 0.25 mg a week to 2.4 mg, and tirzepatide from 2.5 mg in 2.5 mg steps^4,5. In India, the Wegovy FlexTouch and Poviztra pens carry 0.25 to 2.4 mg, and the Mounjaro and Yurpeak KwikPens 2.5 to 15 mg^46,47,48,49.

None of the PCOS studies above compared one GLP-1 medicine with another, so they cannot say which is best^{14,15,16,17,18,19}. The one head-to-head trial, SURMOUNT-5, gave 20.2 % average weight loss on tirzepatide against 13.7 % on semaglutide at 72 weeks⁵⁰. It enrolled 751 adults with obesity and no diabetes, not women with PCOS⁵⁰. Eli Lilly, the maker of tirzepatide, funded it, and it was open-label^50,51.

In India, the indication differs by brand: Mounjaro and Yurpeak for weight and type 2 diabetes, and Ozempic, PharmEasy says, for type 2 diabetes only^1,3,13.

Semaglutide is not approved as a treatment for periods, but small studies report cycle changes alongside weight loss^4,14. In the Italian study of 27 women on 0.5 mg a week, 80 % of those who responded had normal cycles by six months, with no comparison group¹⁴. The Chinese trial of 100 women reported more cycle recovery on semaglutide 1 mg with metformin than on metformin alone¹⁵. The tirzepatide trial of 60 women at 5 mg with metformin reported the same direction¹⁷. In the Danish trial of 72 women on liraglutide 1.8 mg, the bleeding ratio improved more than on placebo¹⁹. The 2026 meta-analysis of 11 trials found the evidence insufficient to draw conclusions on menstrual regularity⁴³.

Semaglutide and period changes: what side-effect reports show

A 2026 analysis of a US database of suspected side-effect reports in all women aged 12 to 55 found heavy bleeding, bleeding between periods and infrequent periods reported more often than expected with semaglutide⁵². For tirzepatide it found bleeding between periods and clots⁵². It counted reports; it did not test whether the medicines caused them⁵².

If cycles return, pregnancy becomes possible: the NHS (UK) says anyone who could get pregnant needs contraception while using semaglutide²⁰. If your bleeding changes, tell your doctor. In India, you can also report a suspected side effect to PvPI, the national programme, on 1800 180 3024 on working days^53,54.

The US Wegovy label says semaglutide (Wegovy, Poviztra and the generics) is stopped at least 2 months before a planned pregnancy, because it stays in the body for a long time⁴. NHS (UK) guidance agrees²⁰. The US label adds that weight loss offers no benefit in pregnancy and may harm the fetus⁴. Wegovy used for weight is stopped in pregnancy⁴. The NHS says semaglutide is not used while breastfeeding²⁰.

For tirzepatide (Mounjaro and Yurpeak), the sources differ. The US Zepbound label says it is stopped when a pregnancy is recognised; the NHS says to stop at least 4 weeks before trying^5,29. Our page on who should not take semaglutide sets out both. The NHS says tirzepatide is not used while breastfeeding²⁹.

Tirzepatide slows stomach emptying, so the US Mounjaro label says it may make the pill work less well⁶. This delay is largest after the first dose⁶. The label advises a non-oral method, or an added barrier method for 4 weeks after the start and after each dose increase⁶. The NHS (UK) gives the same barrier advice²⁹. Non-oral hormonal methods should be unaffected, the label says⁶. For semaglutide, the US Wegovy label says trials at 1 mg a week found no effect on the absorption of oral medicines, and still asks for monitoring⁴.

In the Chinese semaglutide trial, 35 % of the semaglutide group and 15 % of the metformin group became pregnant naturally in weeks 16 to 40¹⁵. By then semaglutide had stopped, and all took metformin alone¹⁵. In the Slovak pilot of 20 women, 60 % became pregnant during follow-up¹⁶. The Slovak women also took metformin, and neither semaglutide nor tirzepatide is approved as a fertility treatment^4,5,16. If a pregnancy happens on treatment, tell your doctor; the NHS says neither medicine is used in pregnancy^20,29.

The Indian weight indications start at a BMI of 30, or 27 with a weight-related condition^1,9,55. In June 2026, CDSCO's expert committee kept the cut-offs in tirzepatide's indication, because obesity is defined differently for US and Asian populations⁵⁶.

The US labels rule these medicines out for anyone with MEN 2 (multiple endocrine neoplasia type 2, a genetic condition) or a personal or family history of medullary thyroid cancer (MTC)^4,5,57. MTC is a cancer of the thyroid's C cells⁵⁸. The NHS says they may not suit anyone who has had pancreatitis^20,29. They are also stopped in pregnancy and before a planned one, and not used while breastfeeding^4,5,20,29.

PharmEasy lists Wegovy, Mounjaro and every semaglutide brand as Schedule H medicines in India, sold only on prescription^3,59,60. A CDSCO committee recommended in 2023 that tirzepatide be prescribed by endocrinologists or internal medicine specialists only; its national scope is not confirmed⁶¹. A health-ministry release of March 2026 names the same specialists, and cardiologists for some uses³⁷. The government advises you to consult a qualified specialist before use³⁵.

A doctor reviews your history, BMI, other conditions, medicines and pregnancy plans, then decides whether a GLP-1 medicine fits the indication. Talk to a Zelta specialist to start that assessment.

What options are available if an unplanned pregnancy occurs? Tell your doctor. The NHS says to report a pregnancy on semaglutide or tirzepatide, and that neither is used in pregnancy^20,29. The US Wegovy label also names a US pregnancy registry⁴.

Do I need contraception on Mounjaro or semaglutide? If you could get pregnant, the NHS says you need contraception on semaglutide²⁰. On Mounjaro, the US label says the pill may work less well⁶. It advises a non-oral method or an added barrier method for 4 weeks after the start and each dose increase⁶.